admin

By the end of this week, the world should cross two small but significant milestones on the road to overcoming COVID-19—getting at least 5% of the global population fully vaccinated against SARS-CoV-2, with at least 10% receiving one dose of vaccines that require two.

According to Our World in Data, a collaboration of the Oxford Martin Programme on Global Development at the University of Oxford and the nonprofit Global Change Data Lab, 376,173,766 people were fully vaccinated as of May 20 (4.8% of global population), while 739,208,299 people had received one dose (9.5%).

The companion diagnostics market is on track to reach $6.8 billion by 2025 (from $3.7 billion in 2020), according to a Markets and Markets report , driven by the growing need for targeted therapy, the rising importance of personalized medicine, the increasing global incidence of cancer, and a raging demand for next-generation sequencing (NGS). So it’s not surprising to see more and more alliances between pharmaceutical companies and diagnostics companies.

LEIDEN, The Netherlands, July 06, 2021 / B3C newswire / — MIMETAS, a leader in organ-on-chip-based disease models and technology, and Roche, a world-leading pharmaceutical company, announced today that they have entered into a collaboration to develop human disease models to characterize novel compounds in inflammatory bowel disease (IBD) and hepatitis B virus infections (HBV). Under the terms of the agreement, MIMETAS is eligible to receive an upfront payment and milestone payments from Roche.

MIMETAS will be responsible for developing tissue-based disease models and assays in the OrganoPlate, its proprietary organ-on-chip platform that increases predictability of biomarkers and reduces animal use in scientific testing. Roche will gain access to technology, disease models, and scientific results. Roche will also receive an option to exclusively license specific disease models and assays for use in drug discovery.

Howard Carolan, Co-Founder and CEO  of CoapTech, Inc., and Neil Davis, Program Director of the Biomedical Entrepreneurship Graduate Certificate program at the University of Maryland Baltimore (UMB), joins Rich Bendis to discuss Startups, Tech Transfer, and the Funding.

Listen now on Google https://bit.ly/36fStWr, Apple https://apple.co/2UpA0UO, Spotify https://spoti.fi/36igrjG, and TuneIn https://bit.ly/3hpCRpT.

Mr. Davis is currently Program Director of the Biomedical Entrepreneurship graduate certificate program at the University of Maryland Baltimore (UMB).  This unique 12 credit graduate certificate provides the student with an opportunity to learn the process of creating valuable intellectual property (IP) and moving it into commercial application.  This process begins with the creation of IP, continues to its licensing and the formation of a venture through the growth of the venture, and culminates with the monetization of that venture.

Thanks to unprecedented development speed and mostly strong safety and efficacy data, vaccines have dominated the response to COVID-19. But ending the pandemic will also require development of numerous therapeutics.

Seven COVID-19 drugs have shown promise recently. Positive signs include the accumulation of encouraging data, participation in the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) trials, and/or progress toward regulatory authorizations.

• This  document  has been  redacted by  Sam Collaudin, Kinexum Business Strategy  Consultant, independently  from any  pharmaceutical and  biotech companies 
• It synthesizes  selected  data presented  during  the  ATTD 2021  conference 
• Grey  rectangles  are  personal  comments and  opinions,  underlined  words are clickable  links  to other  slides  or  external  references 
• If  you  have comments, please  contact me by  email (samcollaudin@kinexum.com) 
• Disclosure: Business  strategy consultant  at Modular  Medical,  CEO  of Abvance Kinexum ,  consultant  for Therapeutics, chairman  of  a non  for profit French health  care  insurance company  (Groupe Operating  Since  2003 Uitsem)

The firm helps gene therapy and vaccine companies develop and manufacture products for rare diseases.

Image: Vigene Biosciences, led by CEO Zairen Sun, right, and Chief Commercial Officer Jeffrey Hung, has been acquired. EMAN MOHAMMED